Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 9/2015

01.09.2015 | Original Article – Cancer Research

Cullin1 is a novel prognostic marker and regulates the cell proliferation and metastasis in colorectal cancer

verfasst von: Weimin Wang, Yansu Chen, Jianliang Deng, Jianping Zhou, Xiancheng Gu, Yuehua Tang, Guoqiang Zhang, Yongfei Tan, Zhijun Ge, Yulin Huang, Shouyu Wang, Jianwei Zhou, Yan Zhou, Sujun Zhou

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 9/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To investigate the precise function of Cullin1 (CUL1) in colorectal cancer (CRC).

Methods

Immunohistochemistry was performed to test the expression of CUL1 on a CRC tissue microarray containing the tumor and corresponding normal tissues. Simultaneously, the correlation of CUL1 expression with clinicopathological parameters and survival was evaluated. CUL1 was over-expressed or knocked down in HCT116 and SW480 cells, then the cell proliferation, migration and invasion assays in vitro and in vivo were performed.

Results

In this study, we found that CUL1 expression was significantly up-regulated in CRC compared with normal colon tissues. High CUL1 expression was positively associated with lymph node metastasis (P = 0.007) and tumor diameter (P = 0.052). Multivariate Cox regression analysis revealed that high CUL1 expression was an independent unfavorable prognostic factor for CRC patients (HR = 13.9, 95 % confidence interval = 5.89–32.6, P < 0.001). Moreover, we found that CUL1 over-expression induced CRC cell proliferation and the growth of xenografts in nude mice via the changing of cell-cycle proteins. In addition, increased CUL1 expression in CRC cells significantly promoted cell migration and invasion abilities in vitro and peritoneal metastasis in vivo through inducing high expression of MMPs.

Conclusion

Our findings imply that CUL1 may serve as promising prognostic markers in CRC patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Bai J, Yong HM, Chen FF, Mei PJ, Liu H, Li C, Pan ZQ, Wu YP, Zheng JN (2013) Cullin1 is a novel marker of poor prognosis and a potential therapeutic target in human breast cancer. Ann Oncol 24:2016–2022. doi:10.1093/annonc/mdt147 CrossRefPubMed Bai J, Yong HM, Chen FF, Mei PJ, Liu H, Li C, Pan ZQ, Wu YP, Zheng JN (2013) Cullin1 is a novel marker of poor prognosis and a potential therapeutic target in human breast cancer. Ann Oncol 24:2016–2022. doi:10.​1093/​annonc/​mdt147 CrossRefPubMed
Zurück zum Zitat Chen G, Li G (2010) Increased Cul1 expression promotes melanoma cell proliferation through regulating p27 expression. Int J Oncol 37:1339–1344PubMed Chen G, Li G (2010) Increased Cul1 expression promotes melanoma cell proliferation through regulating p27 expression. Int J Oncol 37:1339–1344PubMed
Zurück zum Zitat Hynes RO (2003) Metastatic potential: generic predisposition of the primary tumor or rare, metastatic variants-or both? Cell 113:821–823CrossRefPubMed Hynes RO (2003) Metastatic potential: generic predisposition of the primary tumor or rare, metastatic variants-or both? Cell 113:821–823CrossRefPubMed
Zurück zum Zitat Libra M, Scalisi A, Vella N, Clementi S, Sorio R, Stivala F, Spandidos DA, Mazzarino C (2009) Uterine cervical carcinoma: role of matrix metalloproteinases (review). Int J Oncol 34:897–903PubMed Libra M, Scalisi A, Vella N, Clementi S, Sorio R, Stivala F, Spandidos DA, Mazzarino C (2009) Uterine cervical carcinoma: role of matrix metalloproteinases (review). Int J Oncol 34:897–903PubMed
Zurück zum Zitat Salon C, Brambilla E, Brambilla C, Lantuejoul S, Gazzeri S, Eymin B (2007) Altered pattern of Cul-1 protein expression and neddylation in human lung tumours: relationships with CAND1 and cyclin E protein levels. J Pathol 213:303–310. doi:10.1002/path.2223 CrossRefPubMed Salon C, Brambilla E, Brambilla C, Lantuejoul S, Gazzeri S, Eymin B (2007) Altered pattern of Cul-1 protein expression and neddylation in human lung tumours: relationships with CAND1 and cyclin E protein levels. J Pathol 213:303–310. doi:10.​1002/​path.​2223 CrossRefPubMed
Zurück zum Zitat Sun Y, Shen S, Liu X, Tang H, Wang Z, Yu Z, Li X, Wu M (2014) miR-429 inhibits cells growth and invasion and regulates EMT-related marker genes by targeting Onecut2 in colorectal carcinoma. Mol Cell Biochem. doi:10.1007/s11010-013-1950-x PubMedCentral Sun Y, Shen S, Liu X, Tang H, Wang Z, Yu Z, Li X, Wu M (2014) miR-429 inhibits cells growth and invasion and regulates EMT-related marker genes by targeting Onecut2 in colorectal carcinoma. Mol Cell Biochem. doi:10.​1007/​s11010-013-1950-x PubMedCentral
Zurück zum Zitat von Wasielewski R, Mengel M, Wiese B, Rudiger T, Muller-Hermelink HK, Kreipe H (2002) Tissue array technology for testing interlaboratory and interobserver reproducibility of immunohistochemical estrogen receptor analysis in a large multicenter trial. Am J Clin Pathol 118:675–682. doi:10.1309/URLK-6AVK-331U-0V5P CrossRef von Wasielewski R, Mengel M, Wiese B, Rudiger T, Muller-Hermelink HK, Kreipe H (2002) Tissue array technology for testing interlaboratory and interobserver reproducibility of immunohistochemical estrogen receptor analysis in a large multicenter trial. Am J Clin Pathol 118:675–682. doi:10.​1309/​URLK-6AVK-331U-0V5P CrossRef
Zurück zum Zitat Wang S, Wu X, Zhang J, Chen Y, Xu J, Xia X, He S, Qiang F, Li A, Shu Y, Roe OD, Li G, Zhou JW (2013) CHIP functions as a novel suppressor of tumour angiogenesis with prognostic significance in human gastric cancer. Gut 62:496–508. doi:10.1136/gutjnl-2011-301522 CrossRefPubMed Wang S, Wu X, Zhang J, Chen Y, Xu J, Xia X, He S, Qiang F, Li A, Shu Y, Roe OD, Li G, Zhou JW (2013) CHIP functions as a novel suppressor of tumour angiogenesis with prognostic significance in human gastric cancer. Gut 62:496–508. doi:10.​1136/​gutjnl-2011-301522 CrossRefPubMed
Zurück zum Zitat Zheng N, Schulman BA, Song L, Miller JJ, Jeffrey PD, Wang P, Chu C, Koepp DM, Elledge SJ, Pagano M, Conaway RC, Conaway JW, Harper JW, Pavletich NP (2002) Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature 416:703–709. doi:10.1038/416703a CrossRefPubMed Zheng N, Schulman BA, Song L, Miller JJ, Jeffrey PD, Wang P, Chu C, Koepp DM, Elledge SJ, Pagano M, Conaway RC, Conaway JW, Harper JW, Pavletich NP (2002) Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature 416:703–709. doi:10.​1038/​416703a CrossRefPubMed
Metadaten
Titel
Cullin1 is a novel prognostic marker and regulates the cell proliferation and metastasis in colorectal cancer
verfasst von
Weimin Wang
Yansu Chen
Jianliang Deng
Jianping Zhou
Xiancheng Gu
Yuehua Tang
Guoqiang Zhang
Yongfei Tan
Zhijun Ge
Yulin Huang
Shouyu Wang
Jianwei Zhou
Yan Zhou
Sujun Zhou
Publikationsdatum
01.09.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 9/2015
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-015-1931-4

Weitere Artikel der Ausgabe 9/2015

Journal of Cancer Research and Clinical Oncology 9/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.